Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DCVax-L |
Synonyms | |
Therapy Description |
DCVax-L is a lung cancer vaccine composed of patient-derived dendritic cells that have been transduced with a patient tumor-specific antigen, potentially resulting in increased anti-tumor immunity (PMID: 29843811). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DCVax-L | DCVax-Lung | DCVax-L is a lung cancer vaccine composed of patient-derived dendritic cells that have been transduced with a patient tumor-specific antigen, potentially resulting in increased anti-tumor immunity (PMID: 29843811). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02146066 | Expanded access | DCVax-L | Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 | Available | USA | 0 |
NCT03014804 | Phase II | DCVax-L DCVax-L + Nivolumab | Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | Withdrawn | USA | 0 |